Development of targeted nanoparticle drug carriers often requires complex synthetic schemes involving both supramolecular self-assembly and chemical modification. These processes are generally difficult to predict, execute, and control. We describe herein a targeted drug delivery system that is accurately and quantitatively predicted to self-assemble into nanoparticles based on the molecular structures of precursor molecules, which are the drugs themselves. The drugs assemble with the aid of sulfated indocyanines into particles with ultrahigh drug loadings of up to 90%. We devised quantitative structure-nanoparticle assembly prediction (QSNAP) models to identify and validate electrotopological molecular descriptors as highly predictive indicators of nano-assembly and nanoparticle size. The resulting nanoparticles selectively targeted kinase inhibitors to caveolin-1-expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while avoiding pERK inhibition in healthy skin. This finding enables the computational design of nanomedicines based on quantitative models for drug payload selection.
A significant limitation of targeted nanoparticle drug carrier design [1] [2] [3] is that complex synthetic schemes are often required, resulting in low loadings and higher barriers to clinical translation [4] [5] [6] . Until recently, the process of drug encapsulation into stable nano-formulations has been largely experimentally based 7, 8 . However, recent reports on the prediction of nano-formulation in silico suggest that this goal will be a major contribution to the emergence of 'nanoinformatics' , a new sub-field within nanotechnology 9 . In drug carrier design, quantitative structure-property relationship (QSPR) calculations have been used to predict colloidal drug aggregation [10] [11] [12] , drug loading in lipid formulations 13 , and in vivo performance [14] [15] [16] . Molecular dynamics simulations have been used to investigate nanoparticle supramolecular interactions [17] [18] [19] and vehicle selection 20 . However, quantitative approaches have not yet provided appreciable predictive power to enable the design of delivery vehicles de novo based on drug payload selection.
Herein, we found that a subset of sulfated indocyanine dyes selfassemble with hydrophobic drugs to form stable tumour-targeted nanoparticles wherein the formation can be accurately predicted using quantitative information from the structure of the encapsulated drug. Via quantitative structure-nanoparticle assembly prediction (QSNAP) calculations, we identified two molecular descriptors to predict which drugs would assemble with indocyanine into nanoparticles and nanoparticle size with an average accuracy of up to 15 nm. Moreover, this approach also revealed important molecular structure features that enable self-assembly and nanoparticle formation. Importantly, the resulting indocyanine nanoparticles (INPs) were found to encapsulate drugs with high loadings of up to 90% by mass. We assessed the targeted drug delivery properties of two such nanoparticles, encapsulating the tyrosine kinase inhibitors sorafenib and trametinib. Strikingly, we found selective caveolin-1-mediated tumour uptake and exceptional net anti-tumour efficacies in a genetically modified mouse model for hepatocellular carcinoma and a xenograft model for human colorectal cancer. The nanoparticles prevented the inhibition of ERK phosphorylation in the skin, demonstrating that this targeting strategy exhibits strong therapeutic benefits and may obviate skin rash-a doselimiting side-effect of kinase inhibitors.
Indocyanine-stabilized drug nanoparticles
We explored the parameter space of excipients that could facilitate self-assembly of drugs into colloidally-stable nanoparticles with high drug loadings. We estimated that a clinically-useful nanoformulation would contain at least 2 mg ml −1 of drug suspended in water or PBS 21 . We designed a simple nanoprecipitation process to test the propensity of excipient molecules to stabilize hydrophobic drugs within sub-100-nm nanoparticles (Methods). We examined detergents, polyelectrolytes, and lipids previously used to form drug nanocrystals 22, 23 , as well as azo dyes, shown recently to form colloidal drug aggregates 24 . We also tested water-soluble dyes of different classes, including phthalocyanines, triphenylmethanes and cyanines. We then chose an initial set of nine hydrophobic drugs ( Supplementary Fig. 1a ) with poor water solubilities (< 10 µ g ml −1 ). We found that a subset of drugs was able to form stable nanoparticles with sulfated organic dyes from three different dye families: azo, triphenylmethane and indocyanine 25, 26 (Fig. 1a,b , Supplementary  Fig. 1b ). Of these, the indocyanine IR783 most effectively stabilized drugs, resulting in the complete suspension of five out of nine molecules, and relatively small, monodisperse particles 2) .
Dye mixtures were assessed to determine which dyes were most responsible for nanoparticle formation. Nanoprecipitations of sorafenib and paclitaxel with equimolar dye concentrations were found to contain 30-fold more IR783 than Congo Red, and 3-fold more IR783 than Brilliant Blue G, indicating a preference for indocyanine ( Fig. 1c ).
We noted distinct colour changes of the IR783-drug mixtures, depending on whether a given drug was successfully suspended (Fig. 1d ). Absorbance spectroscopy (Fig. 1e ) revealed a relative increase of the IR783 λ max = 780 nm peak and a decrease of the λ max = 640 nm peak, consistent with the dissolution of indocyanine H-aggregates 27, 28 . The 780 nm peak also red-shifted up to 850 nm, suggesting the formation of J-aggregates 29 .
The resulting drug suspensions were characterized by dynamic light scattering (DLS), scanning electron microscopy (SEM), atomic force microscopy (AFM), and transmission electron microscopy (TEM), confirming nanoparticle formation ( Fig. 1f, Supplementary  Fig. 3 ). The drug loading was remarkably high, reaching 90% (mass %) for fulvestrant-based INPs, 84% for paclitaxel INPs, 82% for trametinib INPs, and 86% for sorafenib INPs. Additional characterization data is included in the Supplementary Information ( Supplementary Fig. 3 ). Although the high drug content of these particles resembles that of drug nanocrystals, there are distinct differences, including the lack of high-energy processes in the INP synthesis methods, and particle stability in aqueous solutions free of detergents 23 .
Retrospective quantitative structure-property relationships
We assessed a new library of 16 drug compounds, resulting in eight compounds forming nanoparticles with the indocyanine IR783, while the remainder did not ( Fig. 2a , Supplementary Fig. 4 ). As the compounds were mostly similar in molecular weight, hydrophobicity and charge, we investigated a larger set of chemical properties to understand the factors mediating nanoparticle self-assembly. We employed retrospective QSPR analysis to search for molecular descriptors of drugs which correlated with the successful suspension into nanoparticles. We built a training set of the 16 hydrophobic drug molecules (water solubility < 1 mg ml −1 ) using a binary classification to denote nanoparticle-forming (ranked as 1) and precipitating compounds (ranked as 0), based on the observed stability of the suspensions. We used Dragon 6 software (Talette) to calculate 4,886 descriptors from the molecular structures of the drugs in the training set, which we assessed for correlations with the experimental data of nanoparticle formation (Methods).
The retrospective analysis identified four molecular descriptors that correlated highly with the experimental data for nanoparticle formation, giving Pearson correlation coefficients (r) of greater than 0.85 ( Supplementary Fig. 5 ). One descriptor, SpMAX4_Bh(s), the fourth leading eigenvalue of the Burden matrix, a topochemical index which scores molecules by their geometrical complexity, bond order, and heteroatoms, weighted by the intrinsic state 30 (95% confidence intervals (CI) [0.94, 0.99], Methods). The analysis showed that the calculated eigenvalues of the nanoparticle-forming drugs were greater than 7, while the non-assembling drug eigenvalues were less than 5.5 ( Fig. 2a ). To assess the robustness of this correlation, we compared the training set to 300 randomly generated training sets comprised of the same 16 molecules with scrambled categorization. From these, 80% of the random sets had r values less than 0.7, and the other 20% were less than 0.8; no randomlygenerated training sets had an r value near 0.98 ( Fig. 2b) .
Prediction of nanoparticle self-assembly
To assess the predictive utility of QSNAP Model 1 via the SpMAX4_ Bh(s) descriptor, we calculated SpMAX4_Bh(s) values of 400 hydrophobic drugs (defined as having an ALogP2 value, a molecular descriptor of hydrophobicity, of greater than 4.5). Out of the analysed molecules, we identified 131 compounds with an SpMAX4_Bh(s) value of 6.99 and above. A prospective validation set of 44 molecules was constructed by selecting 19 compounds with SpMAX4_Bh(s) values above 6.99 ( Supplementary Fig. 6 ) and 25 compounds with SpMAX4_Bh(s) values below 6.99 ( Supplementary Fig. 7 ). The validation set was experimentally tested for nanoparticle formation.
Remarkably, all drugs but one (avasimibe) behaved as predicted using SpMAX4_Bh(s), while descriptors for hydrophobicity performed only slightly better than random ( Fig. 2c , Supplementary  Figs. 8, 9 and Supplementary Table 1 ). It is worth noting that two INPs (ABT737 and venetoclax) exhibited low stability in PBS at pH 7.4. This could be explained by the interaction of basic groups in these molecules (pK a s ≥ 8, calculated by ChemAxon), with the sulfate groups on IR783, resulting in destabilization of the nanoparticle.
Mechanistic analysis of predictive QSNAP descriptors
It was apparent that compounds with high SpMAX4_Bh(s) values often contained multiple fluorine atoms; therefore, we compared similar drugs with and without fluorine. Our structural screening revealed two similar molecules, celecoxib, with three fluorine atoms and SpMAX4_Bh(s) = 7.7, and valdecoxib, with zero fluorines and SpMAX4_Bh(s) = 4.7. The drugs behaved experimentally as predicted, where the high-SpMAX4_Bh(s) compound formed nanoparticles but the low-SpMAX4_Bh(s) molecule did not ( Supplementary Fig. 10 ).
We noticed that all four descriptors that correlated highly with nanoparticle formation were weighted by the intrinsic state, so we investigated further. The intrinsic state (I) encodes the electronic state of an atom from the molecular graph as follows:
where L is the principal quantum number of the atom, δ v is the number of valence electrons, and δ is the number of sigma electrons 31 . The calculated intrinsic state values for various atoms show that, indeed, fluorine and groups containing double bonds to oxygen (including carbonyl, sulfoxide, nitro, and so on) exhibit the highest intrinsic state values (8 and 7, respectively, Supplementary  Table 2 ). Further investigation of SpMAX4_Bh(s) reveals that all molecular structures with SpMAX4_Bh(s) values ≥ 6.99 contain at least four atoms with an intrinsic state ≥ 7. Likewise, structures with SpMAX5_Bh(s) ≥ 6.99 have at least five atoms with intrinsic states ≥ 7, and so on ( Supplementary Fig. 11 ).
Simplified QSNAP descriptors for nanoparticle formation
To simplify the prediction process, we created a new descriptor, Number of High Intrinsic State Substructures (NHISS), calculated as the total number of functional groups in a molecule with intrinsic state atoms ≥ 7 (Methods). Comparing NHISS to SpMAX4_Bh(s) for 430 compounds resulted in an agreement of 98.8% (Supplementary Tables 3 and 4 ). We thus conclude that NHISS can replace SpMAX4_Bh(s) to assess nanoparticle formation ( Fig. 2g ).
Prediction of nanoparticle size
We additionally employed QSNAP to predict nanoparticle size. We generated a training set of eight INP-forming drug molecules by measuring particle size by DLS (Supplementary Table 5 and Methods). From the 4,886 descriptors calculated by Dragon 6, we found the GETAWAY R4e correlated strongly with the DLS data; R 2 = 0.84 (95% CI [0.22, 0.98], N = 8, Fig. 2d ). This descriptor is based on the leverage matrix from the spatial coordinates of a molecule using molecular weighting of electronegativity 32 . We then generated a validation set by calculating this descriptor for an additional 18 nanoparticle-forming drugs and measured the INP sizes experimentally. The resulting nanoparticle sizes were successfully predicted by the GETAWAY R4e descriptor within an error of ± 15 nm ( Fig. 2e , Supplementary Table 5 ). To reduce nanoparticle particle sizes to below 100 nm, an optimal dye:drug ratio of 1:5 was found ( Fig. 2f ).
INP assembly prediction of a drug library
We used our predictive model of nanoparticle formation to assess which drugs may form nanoparticles with IR783. We first built a decision tree 11 , to categorize small molecule drugs from the DrugBank database 33 according their ability to self-assemble and likely preparation conditions, based on our new understanding of the chemical properties leading to nanoparticle formation from QSNAP Model 1 and experimental observations of pH-related stability issues (Fig. 2g ). The decision tree incorporates descriptors and chemical features required for nanoparticle formation. Out of 5,653, the analysis predicted that 317 drugs are capable of forming indocyanine nanoparticles and that 295 drugs out of the 317 would be stable in buffer at pH 7.4 (Methods). The category placements of 63 drug molecules in the decision tree were validated experimentally (Supplementary Table 6 ).
Molecular simulations of nanoparticle formation
To better understand the self-assembly process, we conducted all-atom replica exchange molecular dynamics (REMD) simulations 17, 34, 35 . Four indocyanine (IR783) molecules and twelve drug molecules (either sorafenib, a nanoparticle-forming drug, or taselisib, a nonparticle-forming drug) were included in a box with explicit water and run with 32 different temperature replicas for 50 ns ( Supplementary  Fig. 12a ,b, additional details in Methods). The simulations resulted in the formation of indocyanine-drug assemblies with clear morphological differences (Fig. 2h ). The sorafenib-indocyanine simulation formed a significantly more compact assembly than the taselisibindocyanine simulation. In the taselisib simulation, the resulting complex remained relatively loosely assembled, as evident from the relative radial particle density ( Supplementary Fig. 12c ) and solvent accessibility to the drug molecules ( Fig. 2i ). One possible clue to these differences may be the in the number of hydrogen bonds formed in the two simulations. The sorafenib-indocyanine complex formed over four times as many hydrogen bonds compared to the taselisibindocyanine complex (P < 0.001, Fig. 2j ), mainly between the drug molecules themselves ( Supplementary Fig. 12f ).
Kinase inhibitor-encapsulated INPs
Two INPs encapsulating kinase inhibitors were prepared with the indocyanine IR783 for targeting and anti-tumour efficacy studies. Nanoparticles encapsulating sorafenib, a multikinase inhibitor, and trametinib, a MEK inhibitor, were 80 nm and 55 nm in diameter, and exhibited drug loadings of 86% and 83%, respectively. Both nanoparticles were relatively stable in serum and sink conditions for up to 24 h, and they exhibited sustained drug release for over 48 h ( Supplementary Fig. 13 ).
Mechanism of nanoparticle uptake via endocytosis
The internalization of these nanoparticles was studied in multiple cell lines chosen to represent a range of cell types: endothelial cells, epithelial cancers, leukemia, lymphomas, and fibroblasts. Differential uptake was observed across cell types, with a significant preference for endothelial cells, colon cancer cells, and liver cancer cells ( Fig. 3a ). We assessed the mechanism of nanoparticle uptake using various inhibitors of endocytic pathways. Inhibitors of caveolin-mediated endocytosis, but not clathrin-mediated endocytosis, significantly attenuated nanoparticle uptake (Fig. 3b ).
As it has been reported that nanoparticles coated with highly sulfated and aromatic polystyrene sulfonate exhibited differential uptake in cells via caveolae 36 , we hypothesized that the INPs, incorporating a high loading of hydrophobic drug and sparsely coated by sulfated indocyanines, may elicit similar caveolaetargeting effects.
To further investigate the caveolae-targeting hypothesis, we interrogated the Human Protein Atlas and Broad Institute Cancer Cell line Encyclopedia (CCLE) databases for expression levels of CAV1, the main protein scaffold of caveolae ( Supplementary  Fig. 14a ). We found a strong correlation (R 2 = 0.86) between CAV1 expression, assessed by immunohistochemistry ( Supplementary  Fig. 14b ), and the nanoparticle fluorescent signal across cell lines (Fig. 3c ). We also knocked out the CAV1 gene in a colon cancer cell line, HCT116, wherein GFP was also introduced in the vector. We found that the CAV1 knockout exhibited reduced nanoparticle (sorafenib INP) uptake as compared to the wild-type (WT) cells in a co-culture of the two lines ( Fig. 3d ). This difference did not depend on the presence of serum or albumin ( Supplementary Figs. 15, 16 ).
We assessed the ability of the nanoparticles to target three-dimensional tumour spheres in vitro using MCF7 and SK-136 (ref. 37 ) cells in low-adhesion plates (Fig. 3e ). Fluorescent imaging of the tumour spheres after 40 min of incubation with 20 µ g ml −1 of sorafenib INPs revealed a similar pattern to the two-dimensional (2D) cell culture experiments, preferentially targeting the CAV1-expressing SK-136 tumour spheres ( Fig. 3e and Supplementary Figs. 17, 18 ) despite greater interstitial spacing in SK-136 spheres 37 .
Pharmacokinetics and biodistribution in healthy mice
We measured the biodistribution of the indocyanine nanoparticles in healthy mice. After intravenous administration by tail vein injection, the nanoparticles appeared in the liver first-within 20 min. The near-infrared signal from the indocyanine in the lungs increased from 0-24 h ( Supplementary Fig. 19 ). The significant lung accumulation may be explained by the large number of endothelial cells and caveolae present in these organs 38, 39 . At 24 h, a low signal in the liver and spleen was observed. The pharmacokinetics of sorafenib, delivered by INPs and in the free drug form, was measured in healthy mice. The blood half-life of sorafenib INPs was found to be five times longer than that of Kolliphor EL-suspended sorafenib intravenous (i.v.) injection ( Supplementary Fig. 19d ).
Biodistribution of nanoparticles in hepatic tumour model
Next, we evaluated biodistribution of INPs in a MYC-driven murine hepatic tumour model 40, 41 . To generate autochthonous liver tumours, Sleeping Beauty transposon vectors encoding c-Myc and mutant β -catenin (linked to GFP) were hydrodynamically delivered into immunocompetent FVB mice along with a vector encoding Sleeping Beauty transposase (see Methods). At three weeks after inoculation, tumour nodules could be detected in the liver ( Supplementary  Fig. 20a -c), and antibody stains of CAV1 revealed its presence in virtually all tumour vessels as well as larger vessels of normal liver tissue ( Fig. 4a , Supplementary Fig 20d,e ). Fluorescence imaging of livers harvested 24 h after i.v. injection of sorafenib-encapsulated indocyanine nanoparticles revealed localization specifically within tumour tissue, indicated by co-localization of sorafenib INPs and GFP-positive areas (Fig. 4b ). However, we did not observe significant accumulation of sorafenib INPs in normal liver, and free indocyanine did not accumulate in tumours ( Supplementary Fig. 20f ). Microdistribution of the nanoparticles was imaged in frozen sections and revealed both endothelial (stained with CD31) and cancer cell uptake of the nanoparticles (Fig. 4c, Supplementary Fig. 21 ). In addition, sorafenib INPs exhibited little accumulation in liver metastases of uveal melanoma tumours, which lack CAV1 ( Supplementary  Fig. 22 ), suggesting that CAV1 expression mediates specific uptake of sorafenib INPs in vivo.
Efficacy of INPs in hepatic tumours
To test the therapeutic potential of the INPs in vivo, we compared the anti-tumour efficacy of equivalent drug doses in the murine liver cancer model described above, administered intravenously via INPs or orally for the free drug. Sorafenib or sorafenib INPs were injected weekly over the course of three weeks. Strikingly, whereas mice treated with free sorafenib exhibited multiple liver tumours at the experimental endpoint of 60 days, the livers of mice treated with nanoparticles containing the same sorafenib concentration showed virtually no residual tumour tissue, evident by visual inspection, GFP imaging, and histology ( Fig. 4d ). Furthermore, quantitative measures of liver weight, tumour volume, and GFP emission confirmed virtually complete tumour eradication in INP-treated livers ( Fig. 4e-g) . The INP-delivered sorafenib was also more efficacious in comparison to the free drug administered via the same route in a more aggressive version of the model (Methods, Fig. 4h ). A survival study found that 100% of mice administered sorafenib INPs survived, whereas no mice administered the free drug survived (Fig. 4i ).
INP-mediated delivery of a MEK inhibitor
We investigated the biodistribution and anti-tumour efficacy of INPs encapsulating the MEK inhibitor trametinib in a CAV1-expressing colon cancer model which is sensitive to MEK inhibition. The subcutaneous HCT116 human colorectal carcinoma model expresses CAV1 in cancer cells and tumour-associated endothelium (Fig. 5a ).
We assessed the nanoparticle biodistribution in subcutaneous HCT116 xenografts and observed substantial nanoparticle accumulation in tumours ( Supplementary Fig. 23 ). Nanoparticle fluorescence in the tumour tissue was 5-fold higher than in the lungs after 24 h. We compared the anti-tumour efficacy of trametinib INPs to free trametinib. As with sorafenib, a weekly dose of trametinib did not affect tumour progression, but the nanoparticles, encapsulating an equivalent dose of drug, elicited significant tumour inhibition ( Supplementary Fig. 23d ). The anti-tumour efficacy using a weekly dose of 2 mg kg −1 trametinib INPs was comparable to a daily dose of 1 mg kg −1 free trametinib orally, which was cumulatively 2.5 times higher (Fig. 5b) . The trametinib INPs, administered weekly (2 mg kg −1 w −1 ), were as effective as a daily dose of free drug (1 m kg −1 d −1 ), whereas the weekly dose of free trametinib, administered using the same route of administration, resulted in little tumour inhibition (Fig. 5c ).
Toxicity and assessment of off-target MEK inhibition
The toxicities of the INPs and kinase inhibitors were evaluated. Significant mouse weight loss was observed under daily treatments of free trametinib, but no weight loss was apparent for any of the weekly treatments, including with trametinib INPs (Fig. 5d , Supplementary Fig. 23d ). We used the downstream phosphorylation status of ERK as a marker for drug activity 7 . The systemic administration of free trametinib resulted in a pronounced inhibition in ERK phosphorylation in the skin and tumour at 2 h, but pERK returned in both after 24 h. In contrast, trametinib INPs elicited prolonged pERK inhibition in the tumour, including after 24 h, but minimal inhibition in the skin was apparent at that timepoint ( Fig. 5e ). As pERK suppression in the skin is associated with dose-limiting skin rash in humans, these results suggest that the nanoparticles could increase the therapeutic index of MEK inhibitors. Finally, drug/dye distribution ratio in tumours and organs was evaluated by comparing the administration of nanoparticles to free drug and dye in HCT116 xenografts ( Supplementary Fig. 24a-d) .
The nanoparticle formulation showed a similar distribution trend of drug and dye in tumours and organs, while the free molecules distributed differently, with up to a 5-fold ratio difference between the tumours, liver and lungs ( Supplementary Fig. 24e,f) .
Conclusion
This study found a targeted drug carrier nanoparticle, formed by the self-assembly of small molecules, and that the particle selfassembly process can be predicted with an unprecedented degree of certainty via computational methods. The nanoparticles exhibited extremely high drug loadings of up to 90%. Nanoparticles incorporating the kinase inhibitors sorafenib and trametinib selectively targeted CAV1-expressing human colon cancer and autochthonous liver cancer models to yield striking therapeutic effects while preventing inhibition in healthy tissues that normally cause dose-limiting toxicities. The possibility to predict targeted nanoparticle synthesis using molecular structure information of drug compounds presents a significant advancement in the field of drug delivery by facilitating a process that is normally conducted by bench chemistry.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41563-017-0007-z. 
Materials and Reagents. All non-drug chemicals were purchased from Sigma Aldrich (St. Louis, MO). Solvents were purchased from Acros Organics (Morris Plains, NJ). All drugs were purchased from LC-Laboratories (Woburn, MA), except glibenclamide, glimepiride and cyclosporine, which were purchased from Sigma Aldrich, TAK632 from AdooQ Bioscience (Irvine, CA), and talazoparib, fulvestrant, venetoclax, selumetinib and taselisib from Selleckchem (Houston, TX).
Cell lines. All cell lines reported in this study except SK-136 (see details below in tumour spheroids section) were purchased from ATCC (Manassas, VA) and were cultured in DMEM (Life Technologies) medium supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin Streptomycin (Life Technologies) in a 37 °C and 5% CO 2 incubator. Cells were checked for mycoplasma contamination by PCR. The MCF7 cell line is on the ICLAC Register of Misidentified Cell Lines (the contaminating cell line is OVCAR-8), and therefore we used these cells only up to ten passages after receiving the frozen vial directly from ATCC. Our CAV1 immunohistochemistry data for MCF7 is in agreement with the Broad Institute Cancer Cell Line Encyclopedia mRNA data, but not with OVCAR-8.
Preparation of indocyanine nanoparticles. We added 0.1 ml of each drug, dissolved in DMSO (10 mg ml −1 ), dropwise (20 µ L per 15 sec) to a 0.6 ml aqueous solution containing IR783 (Sigma Aldrich, 1 mg ml −1 ) and 0.05 mM sodium bicarbonate or deionized water (for drugs from group 3) under slight vortexing. The solution was centrifuged twice (20,000 g, 30 min), and the pellet was resuspended in 1 ml of sterile PBS. In cases of a pellet that was difficult to re-suspend, it was ultrasonicated for 5 sec with a 1/8 inch probe tip (Sonics & Materials) at 40% intensity. The nanoparticles were lyophilized in a 5% saline/sucrose solution. Absorbance spectra of solutions and suspensions were acquired using a TECAN M1000 plate reader.
Nanoparticle characterization. Dynamic light scattering (DLS) and zeta potential measurements were conducted using a Zetasizer Nano ZS (Malvern). Scanning electron microscopy (SEM) was conducted using a Zeiss Supra 25 Field Emission scanning electron microscope. SEM samples were prepared by gold sputtering and critical point drying. For atomic force microscopy (AFM) measurements, nanoparticles were observed on a freshly cleaved mica surface using an Asylum MFP 3D Bio AFM with an Olympus AC240TS probe. For transmission electron microscopy (TEM), a carbon-coated copper TEM grid (Ted Pella) was used with a JEOL 1200 EX transmission electron microscope operated at 80 kV.
Quantitative structure-nanoparticle assembly prediction (QSNAP). Training set molecules were selected from drugs with solubilities of under 0.1 mg ml −1 in water. Molecular structure mol2 files, obtained from ChemSpider.com, were energy minimized using the ChemBio3D Ultra 14 Suite. We calculated 4,886 molecular descriptors for each molecular structure using Dragon 6 software (Talette). The descriptors were correlated to the binary experimental observations of nanoparticle formation, confirmed by DLS (entered as a rank of 5 in the vector) or precipitation (denoted as a rank of 0) by visual inspection.
QSNAP Model 1: Prediction of INP formation.
The training set consisted of 16 drug molecules which were hydrophobic (water solubility < 1 mg ml −1 ) and highly soluble in DMSO (> 10 mg ml −1 ). 4,886 descriptors from Dragon 6 software (Talette) were calculated, and their correlation with the experimental data of nanoparticle formation was analysed. The descriptor with highest Pearson correlation coefficient (r), SpMAX4_Bh(s), was used for self-assembly prediction. 95% confidence intervals of r were estimated based on a procedure described previously 42 . An SpMAX4_Bh(s) value of 6.99 was observed to be the critical value. Molecules with SpMAX4_Bh(s) values equal to or above 6.99 were predicted to form nanoparticles with indocyanine dye. According to this model, 18 predicted nanoparticle formers and 18 predicted nanoparticle nonformers were picked according to commercial availability, to build a validation set. Nanoparticle formation of the validation set was tested under the same experimental conditions.
QSNAP Model 2: Prediction of INP size.
A training set was formed using eight INP-forming drug molecules with experimentally observed sizes. Using the Dragon 6 software, the GETAWAY R4e descriptor was found to exhibit the greatest correlation to INP size. We built a linear model using the regression module of Microsoft Excel 2010 Data Analysis ToolPak to predict nanoparticle sizes based on the GETAWAY R4e descriptor as follows:
− . Size 48 30(R4e) 0 99
(2)
Coefficients in the above equation were determined by linear regression to eight data points of the training set. 95% confidence intervals of R 2 were estimated based on a procedure described in ref. 42 . The descriptor was calculated for an additional 18 nanoparticle-forming drugs, to be used as a validation set. The nanoparticle sizes were measured experimentally by DLS ( Supplementary Table 3 ).
Molecular dynamics simulations of INP self-assembly. Four indocyanine molecules and twelve drug molecules of sorafenib or taselisib were placed in a 5 nm × 5 nm × 5 nm water box with periodic boundary conditions containing approximately 3,700 TIP3P model water molecules and sodium counter-ions to balance the negative charges of the indocyanine. The total system was comprised of ~ 12,000 atoms. To run the REMD simulations, the Gromacs 4.6.7 simulation package was used with the Charmm36 force field. Long-range electrostatics were calculated using the particle mesh Ewald method with a 0.9 nm real space cutoff. For van der Waals interactions, a cutoff value of 1.2 nm was used. Simulation parameters for the indocyanine and drug particles were obtained from SwissParam (Swiss Institute of Bioinformatics). The indocyanine-drug configurations were energy minimized and subjected to 100 ps NVT equilibration at 300 K. Thirtytwo replicas of the configuration were created with temperatures ranging from 300 K to 563 K. Temperature intervals increased with absolute temperature to maintain uniform exchange probability around 10% acceptance. The 32 replicas were run in parallel for 50 ns of NVT production. Exchange between adjacent temperature replicas was attempted every 2 ps. The time step of the simulation was 2 fs. The trajectories were saved every 10 ps, yielding a total of 5,000 snapshots for production analysis. Structures were visualized in VMD.
Indocyanine nanoparticle self-assembly prediction of DrugBank small molecule drugs. Based on our understanding of the chemical properties leading to drug-dye nanoparticle formation from QSNAP analysis and inspection of 52 drug molecules experimentally determined to form or not form INPs (all drug molecules listed in Table S1 , except the following which were not experimentally tested at the time for INP formation: bithionol, probucol, cholesterol, mubritinib, pyrene, ospemifene and tazarotene), a decision tree was built that categorizes small molecule drugs from DrugBank according their ability to self-assemble and their predicted preparation conditions (Fig. 2g ). We analysed all small molecule type drug entries with reported structures in DrugBank Version 4.5.0 (https://www. drugbank.ca/ released on 20 April 2016) and categorized them according to the decision tree. Simplified Molecular-Input Line-Entry System (SMILES) strings, LogP, strongest acidic pK a and strongest basic pK a values were extracted from DrugBank records. LogP, strongest acidic pK a , and strongest basic pK a are calculated physical properties reported in DrugBank by ChemAxon. All Python scripts used in the analysis, the dataframe of chemical descriptors and partitioning results based on the decision tree ( Fig. 2g) can be found in the nano-drugbank repository, hosted on the collaborative open source software development platform GitHub (http://github.com/choderalab/nano-drugbank). A full list of small molecule drugs from DrugBank predicted to self-assemble into indocyanine nanoparticles according to the decision tree analysis is available as a CSV file in the repository (df_drugbank_decision_tree.csv).
Calculation of the Number of High Intrinsic State Substructures (NHISS)
descriptor. NHISS was calculated as the total number of functional groups in a molecule with intrinsic state atoms ≥ 7. These groups included fluorine atoms (-F) and double-bonded oxygen atoms ( = O). To determine the NHISS scores of a set of molecules, we conducted a substructure search for fluorine, carbonyl, nitro, nitroso, sulfinyl, and sulfonyl functional groups using the SMILES strings of each molecule. A substructure search using SMiles ARbitrary Target Specification (SMARTS) was performed programmatically using the OpenEye OEChem Toolkit. SMARTS used for each functional group and matching substructures patterns are reported in Supplementary Fig. 25 . SMARTS editor and SMARTSviewer 43 were used to generate SMARTS strings that match desired substructures. Number of substructure matches (n) of fluorine, carbonyl, sulfinyl, and nitroso groups incremented the NHISS value by 1, and nitro and sulfone groups incremented by 2. Table 3 , 4) . Python scripts used in the calculation of the NHISS descriptor can be found in the nano-drugbank GitHub repository at https:// github.com/choderalab/nano-drugbank.
Analysis of self assembly prediction performance of hydrophobicity descriptors compared to structure-based descriptors SpMAX4_Bh(s) and NHISS.
To analyse the discrimination performance of logP (OpenEye XlogP, Chem3D ClogP, Dragon ALOGP2), logD (Chemicalize, pH = 7.4), SpMAX4_Bh(s) and NHISS descriptors, Receiver Operating Characteristic (ROC) curves were plotted, using experimental data points (all molecules listed in Table S1 , except pyrene, which was not included in this analysis since it is not a drug) that pass the first decision point of the decision tree: 60 drugs with ChemAxon logP > = 2.2 that were tested for nanoparticle formation.
We computed the area under the curve (AUC) for the receiver-operator characteristic (ROC) function, which measures how much information a descriptor carries about whether the drug will form or not form INPs. An ROC AUC of 0.5 indicates that the descriptor carries no information about whether the drug will form INPs, whereas an AUC of 1.0 indicates the descriptor is perfectly predictive; intermediate values indicate various degrees of predictiveness. This measure is standard in design fields such as virtual screening to assess the relative utility of various predictive models
We computed 95% confidence intervals of the ROC AUC by bootstrapping experimental data: the dataset of 60 drug molecules was resampled 1000 times with replacement. Confidence intervals are estimated based on the distribution of AUC values of resampled datasets of size 60. Python scripts used for the performance comparison of QSNAP Model 1 descriptors (NHISS and SpMAX4_Bh(s)) and various hydophobicity descriptors are available in the IR783-QSNAP GitHub repository at https://github.com/choderalab/IR783-QSNAP.
Drug release measurements. Nanoparticles were incubated in PBS at pH 5.5 and 7.4 at 37 °C or with serum with a concentration equivalent to 1 µ M of drug. The amount of released drug was determined by extracting into ethanol/acetonitrile and measuring the absorbance at 260 nm (for sorafenib) and 314 nm for trametinib using a UV-VIS-NIR spectrophotometer (Jasco 670) or plate reader (Tecan Infinite M1000). All experiments were carried out in duplicate.
Protein adsorption. Protein adsorption was evaluated using surface zeta potential measurements of nanoparticles incubated with escalating doses of bovine serum albumin (BSA) (0-40 mg ml −1 ). Measurements were performed 15 min after incubation with BSA with a Malvern Zetasizer Nano ZS system. Nanoparticle uptake in cell lines. Cell lines bEnd.3, BAEC, SK-136, L3, MCF7, and HL60 were used. The cells were plated in a 24-well plate (50,000 cells in 1 ml) and incubated with 20 μ g ml −1 of nanoparticles for 45 min and with CellMask Green (Life Technologies) for another 15 min to stain cell membranes and Hoescht 33342 (Life Technologies) to stain nuclei. The cells were rinsed twice with PBS. Images were acquired with an inverted Olympus IX51 fluorescent microscope equipped with an XM10IR Olympus camera and an Excite Xenon lamp. Similar exposure times and excitation intensities were applied throughout all experiments. Filter sets: cell membrane: ex 488 nm, em 525 nm, nucleus: ex 350 nm, em 460 nm, IR783 dye in particles: ex 780 nm, em 820 nm. Images were processed with ImageJ software.
Development of tumour spheroids.
To generate multi-cellular tumour spheroids, we developed a cell line, SK-136, derived from the autochthonous liver cancer model. The cells were generated and harvested from c-MYC/β -catenin amplified hepatoblastoma cells from FVB mice using a method described previously. The harvested cells were plated on ultralow-attachment 96-well plates (Corning) and incubated for three days. The wells were examined with an inverted light microscope to confirm the formation of multicellular tumour spheroids. The wells containing tumour spheres were centrifuged, trypsinized, and seeded in 75 cm cell-culture-treated flasks with DMEM. This process was repeated three times to generate a sub-clone of spheroid-forming cells. To identify CAV1 expression in 7-day-old tumour spheroids, they were collected at the bottom of an Eppendorf tube, suspended in paraformaldehyde, and embedded in paraffin. 10 µ m slices were stained with anti-caveolin-1 antibody (Cell Signaling, cat no. 3267, 1 µ g ml −1 ) as well as haemotoxylin and eosin (H&E) staining. To characterize the surface of the tumour spheroids, SK-136 cells were grown in ultralow-attachment flasks (Corning) for five days. Once the spheres were formed, the media containing tumour spheres was removed and placed in 1 ml Eppendorf tube. The spheres were allowed to settle by gravity for 2 min and the media was replaced with fresh media. The spheroids were placed on poly-l-lysine-coated plastic coverslips (Thermonex). The spheroids were then fixed in 2.5% paraformaldehyde in 0.075 M cacodylate buffer for one hour, rinsed in cacodylate buffer, and dehydrated in a graded series of alcohols: 50%, 75%, 95% and 100%. The samples were then dried in a JCP-1 Critical Point Dryer (Denton). The coverslips were attached to SEM stubs and sputter-coated with gold/palladium using a Desk IV sputter system (Denton Vacuum). The images were obtained in a Scanning Field Emission Supra 25 scanning electron microscope (Zeiss).
Penetration of nanoparticles in tumour spheroids. 10 4 SK-136 cells were seeded in 25 cm 2 ultralow attachment flasks (Corning) and grown for seven days in DMEM with media replacement every three days. When spheres reached a diameter of approximately 250 µ m, 0.2 ml of growth suspension was plated in normal adhesion 96-well plates, yielding 3-5 spheres per well. After 30 min, spheres adhered to the bottom of the wells. Nanoparticles were added at a concentration of 50 µ g ml −1 and incubated for 20-40 min. The wells were washed three times with HBSS buffer and imaged with an inverted Olympus IX51 fluorescence microscope equipped with a XM10 Olympus CCD camera. The fluorescence intensity was analysed using ImageJ software.
Animal Studies. All of the animal studies were conducted according to protocols approved by the Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use Committee (IACUC). Mice were maintained and treated in accordance with the institutional guidelines of the Memorial Sloan Kettering Cancer Center.
MYC/β-catenin driven liver tumour studies. Hydrodynamic transfection of C-MYC and β -catenin was performed as follows: 10 μ g pT3-EF1a-c-myc, 10 µ g pT3-EF1a-β -CateninT41A-IRES-GFP and CMV-SB13 Sleeping Beauty transposase (1:5 ratio) were mixed in sterile saline solution. A total volume of plasmid-saline solution mix corresponding to 10% of the body weight was injected into the lateral tail vein of 6-to 8-week-old female FVB/N mice (Jackson Laboratory, Maine, USA) within 5-7 seconds. Mice were administered either 30 mg kg −1 sorafenib orally, or 30 mg kg −1 sorafenib in sorafenib INP form via tail vein injection. For targeting and biodistribution experiments, mice were injected with sorafenib INPs or indocyanine 3 weeks and 6 weeks after transfection. Livers were harvested 24 h after injection. For efficacy studies, treatments were administered weekly for three weeks. Livers were harvested at day 59. Tumours were evaluated using fluorescence imaging (IVIS imaging system, Xenogen Corp., Hopkinton, MA) and immunohistochemistry (H&E). Tumour volume was measured using a caliper. For the aggressive model 20 μ g pT3-EF1a-cmyc, 20 µ g pT3-EF1a-β -CateninT41A-IRES-GFP and CMV-SB13 Sleeping Beauty transposase were used (double that above).
Colon cancer xenograft studies. Six-week-old female athymic NU/NU nude mice purchased from Charles River Laboratories were injected with 5 × 10 5 of HCT116 human colorectal carcinoma cells subcutaneously in 100 ml culture media/Matrigel (BD Biosciences) at a 1:5 ratio. Animals were randomized at a tumour volume of 70 to 120 mm 3 into four to six groups, with n = 8-10 tumours per group. Animals were treated per os (p.o.). with trametinib (1 mg kg −1 ) or i.v. with trametinib INPs (1 mg kg −1 ) once a week. Tumour size was measured with a digital caliper, and tumour volumes were calculated using the formula: (length x width 2 ) x (π /6). Animals were euthanized using CO 2 inhalation. Mice were housed in air-filtered laminar flow cabinets with a 12-hr light/dark cycle and food and water ad libitum.
Blood pharmacokinetics. Serial blood samples were collected in lithiumheparin-containing tubes before and at 0.05, 0.5, 2, 4, 24 and 48 h after the administration of the first dose of sorafenib INPs or free sorafenib in Kolliphor EL. Samples were processed within 30 min of collection by centrifugation for 10 min at 1500 g under refrigeration (~ 4 °C). The resultant plasma was stored at − 70 °C until subsequent analysis for sorafenib using a validated liquid chromatography/tandem mass spectrometry method. Briefly, sorafenib was extracted from plasma using acetonitrile precipitation. Separation of sorafenib, C18 (150 mm × 2.1 mm internal diameter, 3.5 μ m; Agilent Technologies USA) analytical column using a mobile phase consisting of acetonitrile containing 0.1% trifluoroacetic and deionized water containing 0.1% trifluoroacetic. The gradient from 0 to 95% acetonitrile in 17 min and flow at 1 ml min −1 showed a retention time of 12.5 min and absorbance at 280 nm.
In vivo imaging of INPs with IVIS. 24 h after tail vein injection of 200 μ l (1 mg ml −1 ) INP (sorafenib, trametinig, fulvestrant and valrubicin). Organs were extracted and placed on a Petri dish (liver, kidney, lungs, heart, spleen and tumour if present). Images were taken with an IVIS imaging system (Xenogen Corp.). Radiance efficiency (photons sec −1 cm −2 ) was calculated for the tumour region of interest (ROI) using LivingImage V4.2 software.
Drug biodistribution. 24 h after administration of nanoparticles or free drugs, the organs were cut into small pieces, homogenized with lysis buffer, and the drugs mixed with chloroform overnight. The solution mixture was filtered and the homogenate was treated twice with chloroform with repeated filtration. Chloroform was evaporated under vacuum and reconstituted in chloroform-d6. 19F-NMR spectroscopy was applied for fluorine quantification which arises solely from the drugs.
Liver metastasis model of uveal melanoma in NOD SCID GAMMA (NSG mice). Human liver metastatic-enriched uveal melanoma cells expressing GFPluciferase (L3 from OMM-1 cells, ATCC) were supplied by V. Rajasekhar. 5 × 10 5 cells were injected via the retro-orbital sinus on NSG mice (JAX Laboratories). The appearance of liver metastases by bioluminescence was observed within 14 days after inoculation. Nanoparticles were injected 24 h before imaging (with an IVIS imaging system, Xenogen Corp., Hopkinton, MA).
Immunohistochemistry. For xenograft samples, dissected tissues were fixed immediately after removal in a 10% buffered formalin solution for a maximum of 24 h at room temperature before being dehydrated and paraffin-embedded under vacuum. The tissue sections were deparaffinized with EZPrep buffer (Ventana Medical Systems). Antigen retrieval was performed with CC1 buffer (Ventana Medical Systems), and sections were blocked for 30 min with Background Buster solution (Innovex).
The immunohistochemical detection was performed at the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center using a Discovery XT processor (Ventana Medical Systems). All the tissues were harvested from mice and fixed in 4% PFA overnight. Fixed tissues were dehydrated and embedded in paraffin before 5 µ m sections were put on slides. The tissue sections were deparaffinized with EZPrep buffer (Ventana Medical Systems), antigen retrieval 1 nature research | life sciences reporting summary Corresponding author(s): Daniel A. Heller
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Experimental design 1. Sample size
Describe how sample size was determined. Sample sizes were chosen based on previous literature in nanomedicine and tumor biology, and our own expertise.
Data exclusions
Describe any data exclusions.
No data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
Myc/b-cathenin liver cancer model was repeated 3 times. HCT116 colon cancer xenografts experiments were done 3 times.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For HCT116 xenografts, we used stratified randomization: 7 days after tumor inoculation the tumor volume was measured and mice were randomized to different cages so that the average tumor volume will be similar in all groups. in the liver cancer model we used simple randomization -meaning the assignment of inoculated mice to a treatment was random.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The survival experiment of liver cancer bearing mice was blinded as the person taking the data did not know which groups were treated or not (done by animal core facility). For tumor volume experiments we didn't use blinding because it's a quantitative objective measurement.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
